The DOI matches its Crossref record; the references it cites are not checked yet.
Narrative Review of Effects of Glucagon-Like Peptide-1 Receptor Agonists on Bone Health in People Living with Obesity
Abstract
Glucagon-like peptide-1 Receptor agonists (GLP-1Ras) such as liraglutide and semaglutide have been recently approved as medications for chronic weight management in people living with obesity (PwO); GLP-1 may enhance bone metabolism and improve bone quality. However, the effects of GLP-1Ras on skeletal health remain to be determined and that's the purpose of this narrative review. Nevertheless, bone consequences of intentional weight loss interventions in PwO are well known: (i) significant weight loss induced by caloric restriction and bariatric surgery results in accelerated bone turnover and bone loss, and (ii) unlike caloric restriction interventions, PwO experience a substantial deterioration in bone microarchitecture and strength associated with an increased risk of fracture after bariatric surgery especially malabsorptive procedures. Liraglutide seems to have a positive effect on bone material properties despite significant weight loss in several rodent models. However, most of positive effects on bone mineral density and microarchitecture were observed at concentration much higher than approved for obesity care in humans. No data have been reported in preclinical models with semaglutide. The current evidence of the effects of GLP-1Ra on bone health in PwO is limited. Indeed, studies on the use of GLP-1Ra mostly included patients with diabetes who were administered a dose used in this condition, did not have adequate bone parameters as primary endpoints, and had short…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These limited findings align with pre-clinical data suggesting GLP1Ra-based therapies may positively impact bone health by promoting bone formation and reducing bone turnover (12, 44).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [44]
In the citing paper
“The effects of GLP-1 RAs have been investigated in a limited number of studies, primarily focusing on obese individuals with T2DM, yielding heterogeneous results [41].”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [41]
Citations
The citation lists are queued
They are fetched later and appear here then.
References 87 · Cited by 50
Research works printed but not linked: 4
- Schlienger JL, Monnier L (2023) Co-agonistes des récepteurs du GIP et du GLP-1: une innovation thérapeutique majeure dans le traitement du diabète de type 2. Med Mal Metab 17:49–57
- Papageorgiou M, Biver E (2023) Bone consequences of intentional weight loss in overweight or obese patients. Rev Med Suisse 19:756–760
- Iepsen EW, Lundgren JR, Hartmann B et al (2015) GLP-1 receptor agonist treatment increases bone formation and prevents bone loss in weight-reduced obese women. J Clin Endocrinol Metab 100(8):2909–2917. https://doi.org/10.1210/jc.2015-1176 · DOI · Paper page
- Cai TT, Li HQ, Jiang LL, Wang HY, Luo MH, Su XF, Ma JH (2021) Effects of GLP-1 receptor agonists on bone mineral density in patients with type 2 diabetes mellitus: a 52-week clinical study. Biomed Res Int 17(2021):3361309
Metadata
- Authors
- Herrou, J., Mabilleau, G., Lecerf, J.-M., Thomas, T., Biver, E., & Paccou, J.
- Affiliations
- Inserm (FR)
- Institut Pasteur de Lille (FR)
- University of Geneva (CH)
- Université de Lille (FR)
- Corresponding author
- Paccou, Julien
- ORCID
- Venue
- Calcified Tissue International
- Published
- 2023-11-24
- Volume
- 114
- Issue
- 2
- Pages
- 86-97
- ISSN
- 0171-967X (ISSN-L)
- 1432-0827
- OpenAlex
- W4388977425
- Cited by
- 50
- References
- 87
- Citations by year
- 2026: 13 · 2025: 24 · 2024: 12
- FWCI
- 2.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Calcified Tissue International (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, obesity, bone health, liraglutide, semaglutide, weight loss, bone mineral density, bone microarchitecture, fracture risk, bariatric surgery, caloric restriction, bone turnover
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Obesity, Weight Loss, Bone Density, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Narrative Review of Effects of Glucagon-Like Peptide-1 Receptor Agonists on Bone Health in People Living with Obesity. https://app.cochat.ai/papers/10.1007/s00223-023-01150-8
- The paper
- Herrou, J., Mabilleau, G., Lecerf, J.-M., Thomas, T., Biver, E., & Paccou, J. (2023). Narrative Review of Effects of Glucagon-Like Peptide-1 Receptor Agonists on Bone Health in People Living with Obesity. Calcified Tissue International. https://doi.org/10.1007/s00223-023-01150-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.